$CVGW

Short Interest in Calavo Growers, Inc. (NASDAQ:CVGW) Expands By 36.3%

Short interest in Calavo Growers, Inc. (NASDAQ:CVGW) increased by 36.3% in January, reaching 720,472 shares, which represents about 4.3% of the stock. This surge in short interest comes after the company missed its recent quarterly earnings and revenue estimates. Despite a "Hold" rating from analysts with a consensus price target of $33.50, the company recently announced a quarterly dividend of $0.20 per share.

Original reporting
MarketBeat · MarketBeat
Published Feb 2, 2026, 7:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 2, 2026, 7:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Short Interest in Calavo Growers, Inc. (NASDAQ:CVGW) Expands By 36.3% — source image
Decision brief

The 30-second read

$CVGWBearishMed
01

Why it matters

The surge in short interest indicates increased bearish sentiment, which could lead to downward pressure in the near term, but the company's dividend and analyst outlook may provide support.

02

Market read

The news is moderately relevant for traders focusing on short-term movements in CVGW, especially given the earnings miss and short interest increase.

03

What to watch

Possible upcoming company disclosures or sector-wide trends that could offset bearish signals; dividend payout might support share price.

Timing: short-term (within days to weeks)

Background

Calavo Growers, Inc. experienced a 36.3% increase in short interest in January, reaching 720,472 shares, amid a recent earnings miss and a 'Hold' rating with a $33.50 target.

Company-level read

Ticker impact

$CVGWBearishMedium confidence
Context

The news about increased short interest in Calavo Growers, Inc. (NASDAQ:CVGW), especially after earnings miss, has moderate relevance for trading decisions.

Expected impact

Potential short-term decline or increased volatility; long-term impact uncertain without further fundamentals.

Evidence & confidence

The rise in short interest and earnings miss are clear facts; however, the overall market reaction can be influenced by other factors such as dividend announcement and analyst ratings.

Market effects

The food and agricultural sector may experience increased scrutiny or cautious trading due to this company's earnings and short interest activity.

Limited regional impact; primarily affects investors and traders in the U.S. market.

Low; specific to Calavo Growers and its sector.

Counterpoint

The earnings miss and increased short interest could be overreactions; the company's dividend and stable analyst ratings suggest potential for recovery or stabilization.

Key entities

  • Calavo Growers, Inc.

    A provider of fresh and processed avocados and other perishable foods.

  • MarketBeat

    Source of the news report.

Related articles

$GDMedAI 9/10

General Dynamics wins $249m in US military contracts

General Dynamics (GD) won two U.S. military contracts totaling $248.9M. One is a $149.6M contract for USS Pinckney modernization, with potential value up to $149.9M. The other is a $99.3M task order for MUOS Ground Infrastructure Segment upgrades. Both contracts are sole-source and involve work through 2028, funded by fiscal 2026 budgets.

$LMTHighAI 9/10

Lockheed Martin wins $150 million in defense contracts

Lockheed Martin Corp received three contract modifications worth over $150 million from the U.S. Department of Defense. The largest, $90.2 million, is for the TRIDENT II Life Extension 2 program, with work spread across multiple locations. The other contracts, $40.1 million and $20.3 million, are for the MK 41 Vertical Launching System and HH-60W repairs, respectively. Completion dates range from 2027 to 2030.

$NVSMedAI 8/10

Novartis Pharma AG: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announced that the Phase III Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint of reducing cardiovascular events. The study, involving 8,323 patients, showed that while pelacarsen lowered Lp(a) levels, it did not reduce cardiovascular risk. Novartis obtained rights to pelacarsen from Ionis Pharmaceuticals. Elevated Lp(a) affects about 20% of people worldwide and has no approved targeted treatment.

$DELLMed

3 AI Stocks to Buy (and 2 to Skip) as the AI Buildout Hits a New Gear

Microsoft, Google, and Dell reported strong earnings and growth. Dell's revenue grew 58% YoY, with AI server backlog at $60.9B. Credo Technology Group saw 115% revenue growth but faced stock decline due to margin concerns. Fervo Energy secured a major geothermal deal with Google. FuelCell Energy and Eos Energy Enterprises also reported updates. The article discusses AI and energy sector trends, highlighting liquidity issues and strong fundamentals.

$MUMed

Analyst Has Strong Take on Micron, SanDisk Stocks

Lynx Research predicts breakouts for Micron (MU) and SanDisk (SNDK), assigning targets of $1,325 and $2,450, implying 31.7% and 41.9% upside. The firm cites reduced volatility and steady buying in the memory sector. Both companies benefit from tightening supplies and AI demand. MU's volatility eased in August, while industry fundamentals remain supportive.